The Saccharomyces cerevisiae protein SEC14p is required for Golgi function and cell viability in vivo. This requirement is obviated by mutations that specifically inactivate the CDP-choline pathway for phosphatidylcholine biosynthesis. The biochemical basis for the in vivo relationship between SEC14p function and the CDP-choline pathway has remained obscure. We now report that SEC14p effects an in vivo depression of CDP-choline pathway activity by inhibiting choline-phosphate cytidylyltransferase (CCTase; EC 2.7.7.15), the rate-determining enzyme of the CDP-choline pathway. Moreover, this SEC14p-mediated inhibition of CCTase was recapitulated in vitro and was saturable. Finally, whereas the SEC14p-dependent inhibition of CCTase in vitro was markedly reduced under assay conditions that were expected to increase levels of phosphatidylinositol-bound SEC14p, assay conditions expected to increase levels of phosphatidylcholine-bound SEC14p resulted in significant potentiation of CCTase inhibition. The collective data suggest that the phosphatidylcholine-bound form of SEC14p effects an essential repression of CDP-choline pathway activity in Golgi membranes by inhibiting CCTase and that the phospholipidbinding/exchange activity of SEC14p represents a mechanism by which the regulatory activity of SEC14p is itself controlled.
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The Saccharomyces cerevisiae protein SEC14p is a member of a ubiquitous class of proteins, the glycerophospholipid (PL)-transfer proteins, that were identified in assays measuring protein-catalyzed transfer of lipids between membrane bilayers in vitro (1) (2) (3) . While there has been much speculation with regard to the in vivo involvement of such proteins as diffusible carriers of lipid in intracellular lipid trafficking and lipid sorting events (1, 2) , the availability of secl4 mutant strains of yeast has provided the first system with which the in vivo function of a PL-transfer protein can be studied in detail.
SEC14p is a phosphatidylinositol/phosphatidylcholine (PI/ PC)-transfer protein that localizes as a peripheral Golgi membrane protein and is required for both transport of secretory glycoproteins from a late Golgi compartment and cell viability (4) (5) (6) . Penetrating clues as to the function of SEC14p in vivo were obtained from genetic studies revealing that the SEC14p requirement for Golgi secretory function and cell viability was bypassed by specific inactivation of the CDP-choline pathway for PC biosynthesis (refs. 7 and 8; Fig.  1A ) and from biochemical studies indicating that the primary consequence of SEC14p dysfunction in vivo is a specific CDP-choline pathway-driven increase in Golgi PC (9) . This increase is accounted for by one of two mechanisms: (i) that SEC14p maintains a reduced Golgi membrane PC content by
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PC removal from Golgi membranes via PC transfer or (ii) that SEC14p represses the CDP-choline pathway in yeast Golgi membranes via a PL-sensing mechanism that effects downregulation of CDP-choline pathway in response to the PL content of yeast Golgi membranes (9) .
The sensor model makes two distinguishing predictions. First, it posits that SEC14p specifically represses the activity of at least one of the three structural enzymes of the CDP-choline pathway. Second, it predicts that the inhibitor activity of SEC14p is controlled by whether PI or PC is bound to SEC14p . We now present in vivo and in vitro data to indicate that SEC14p depresses CDP-choline pathway activity by inhibiting CCTase, the rate-determining enzyme of the CDP-choline pathway. The data further suggest that SEC14p-PC is the inhibitory agent and that the phospholipid-binding/exchange activity of SEC14p represents a mechanism by which the CCTase-directed regulatory activity of SEC14p is itself controlled. (9) (10) (11) (12) . When appropriate, minimal defined medium was supplemented with 1 mM inositol and/or choline.
MATERIALS AND METHODS
[14C]Choline Labeling and Phospholipid Quantitation. Procedures for choline labeling, quantitation and normalization of 14C incorporation, phospholipid extraction, and thinlayer chromatography have been described (9, 13 (9) . Wildtype strains converted 7.2% of incorporated label (1.2 x 106 cpm) into PC under these conditions. Incorporation of radiolabel by the strains employed were linear during the course of the radiolabeling, and the efficiencies of incorporation of radiolabel into each of the strains employed were similar under these conditions (data not shown). The strains employed included CTY525 (wild-type), the YEp(SEC14) strain CTFY521 (SEC14p overproducer), the YEp(SEC14sP) strain CTY457
[the Schizosaccharomyces pombe SEC14p (SEC14psP) overproducer], CTY541 (cki:.HIS3), CTY553 (cct::URA3), and CTY522 (cptl::LEU2). In the case of the SEC14psP overproducer strain CTY457, SEC14psP expression was constitutively driven from SEC14SP cDNA by the ADH1 promoter of S. cerevisiae, and SEC14psP represented the sole SEC14p species in the yeast cells.
amine-free medium supplemented with 1 mM choline and 1 mM inositol and labeled to steady state with [32P]orthophosphate (9) . Total cell phospholipids were extracted, resolved, and quantitated as described (9, 14, 15) .
Purification of SEC14p. Hexahistidine-tagged SEC14p was isolated either from yeast overproducing the active recombinant SEC14p or from Escherichia coli expressing the same. SEC14p-overexpressing cells were collected, resuspended in 50 mM potassium phosphate, pH 7.5/300 mM NaCl/2 mM phenylmethanesulfonyl fluoride and disrupted in a Bead Beater (Biospec Products, Bartlesville, OK). The homogenate was serially clarified at 5000 x g, 12,000 x g, and 100,000 x g. Yeast-derived SEC14p was precipitated at 50-70% saturation with ammonium sulfate, whereas E. coli-derived SEC14p precipitated at 50% saturation with ammonium sulfate. Precipitates were resuspended in 50 mM potassium phosphate, pH 7.5/300 mM NaCl/2 mM phenylmethanesulfonyl fluoride, dialyzed, loaded onto a column of Ni+-NTA resin (Qiagen, Chatsworth, CA), and eluted with a linear gradient of (0-200 mM) imidazole in 50 mM potassium phosphate, pH 7.5/300 mM NaCl. Fractions were assayed for PI and PC transfer activities (16) (Fig. 1B) . Further, the SEC14p overproduction-mediated effect correlated well with SEC14p function in vivo, as a 73% depression in CDP-choline pathway activity was observed upon high-level expression of (SEC14psP) in S. cerevisiae. SEC14psp scores as a fully functional SEC14p when expressed in S. cerevisiae (data not shown). We interpret the SEC14p overproduction-mediated repression of CDP-choline pathway activity to represent the extension of a Golgi membranespecific regulation of the CDP-choline pathway to a bulk intracellular effect. SEC14p overproduction has no measurable effect on the rate of PC biosynthesis via the PE methylation pathway (9) .
CCTase Is the Target for SEC14p-Mediated Repression in Vivo. To determine which step of the CDP-choline pathway was sensitive to repression by SEC14p overproduction, we took advantage of our observation that SEC14p overproduction in vivo manifested itself in a significant reduction in bulk membrane PC at steady state ( (Fig. 2A) . This inhibition was specific, as SEC14p (100-500 units) failed to diminish CKIase or CPTase activity ( Fig. 2A) (Fig. 3A) . CCTase specific activity was insensitive both to the changes in bulk membrane PL composition induced by such manipulations of growth medium and to the addition of exogenous PC vesicles to assay mixtures containing I+C-membranes (Fig. 3B) . The potency of SEC14p inhibition of CCTase, at subsaturating levels of SEC14p, was then determined as a function of the PL composition of the membranes in the CCTase challenge assays.
The standard condition for any given concentration of SEC14p was defined as the SEC14p inhibition profile obtained when bulk membranes prepared from YPD-grown cells were used as the source of CCTase (Fig. 3C) (Fig. 3C) . When I+C-membranes were used, these amounts of SEC14p failed to significantly inhibit CCTase. In the presence of exogenous PC vesicles, however, 5 and 10 units of SEC14p effected 50% and 70% inhibition of CCTase activity, respectively (Fig. 3C) 28.3 ± 0.9 Bulk membrane steady-state phospholipid compositions were determined for the designated yeast strains grown in glucose-supplemented or galactose-supplemented minimal medium at 25°C. Relevant genotypes of the strains are given. The PL content per unit cell for all of these strains was similar (9) . Hence, the data for each individual PL species are presented as a mole percentage of total PL. PLs were extracted and resolved (Materials and Methods), and individual PLs were quantitated both by 32P radiolabeling and by inorganic phosphate determination (14, 15) . PS, phosphatidylserine.
PI; 24 nmol of total vesicle PL) were substituted for PC vesicles in CCTase assays, the potentiation of SEC14p-mediated inhibition was eliminated (5 and 10 units of SEC14p effected 10% and 18% inhibition of CCTase activity, respectively (data not shown). Finally, introduction of vesicles containing PLs (1:1 molar ratio of PE to sphingomyelin) that are not binding substrates for SEC14p did not measurably affect the SEC14p-mediated CCTase inhibition profile in assays employing I+C-membranes (data not shown). These data indicated a PL modulation of SEC14p-mediated inhibition of CCTase and strongly suggested that SEC14p-PC inhibited CCTase whereas SEC14p-PI did not.
DISCUSSION
Two independent lines of in vivo evidence identify CCTase as the SEC14p target. First, SEC14p-overproducing yeast strains experienced both a specific depression in the bulk activity of the yeast CDP-choline pathway in vivo and a reduction in bulk membrane PC at steady state. The latter effect exhibited the signature of CCTase deficiency and was precluded by disruption of the CCTase structural gene ( Fig. 1 tants reflects a combination of (i) the lack of functional redundancy between ethanolamine-phosphate cytidylyltransferase and CCTase activities in vivo and (ii) functional redundancies associated with ethanolamine kinase and ethanolamine phosphotransferase driving the steady-state correction of CKIase and CPTase defects in bulk membrane PC, respectively (23) . Second, overproduction of CCTase suppressed the SEC14p overproduction-mediated reduction in bulk membrane PC (Table 1) . CCTase represents a physiologically reasonable target for regulation by SEC14p, as it catalyzes the rate-determining step in the yeast CDP-choline pathway in vivo (24) . The identification of CCTase as the SEC14p target also fulfills the major prediction of the sensor model; i.e., that activity of a CDP-choline pathway enzyme will be inhibited by SEC14p.
The case for SEC14p-mediated inhibition of CCTase was further supported by our ability to recapitulate this effect in vitro by using recombinant SEC14p purified either from yeast or from E. coli (Fig. 2) . While we have not determined whether SEC14p physically interacts with CCTase, the inhibition of CCTase by SEC14p in vitro was specific, as SEC14p failed to depress either CKIase or CPTase activity in vitro ( Fig. 2A) (Fig. 2B) . Lastly, the finding that the potency of SEC14p-mediated inhibition of CCTase was a function of membrane PC content suggested that SEC14p-PC was the CCTase inhibitor (Fig. 3C) (Fig. 4) 
